Table 4.
Other Studies Evaluating BRCA Mutations in Patients With Pancreatic Adenocarcinoma
| Study | Population | BRCA1 | BRCA2 | % |
|---|---|---|---|---|
| Hahn et al7 | Familial* (n = 26 families, n = 64 individuals) | No | 4075delGT | 19 (n = 3 families) |
| 6672insT | ||||
| 6819delTG | ||||
| R2034C | ||||
| G3076E | ||||
| 10323delCins11 | ||||
| Goggins et al10 | Sporadic (n = 245) | No | (n = 4) 6174delT 6158insT | 9.8 |
| Ozcelik et al9 | Ashkenazi Jews (n = 39) | No | 4 (6174delT) | 10 |
| Murphy et al8 | Familial† (n = 29 families) | No | (n = 5) 6174delT | 17 |
| Point mutation M192T | ||||
| Two splice mutations | ||||
| This study | Jewish patients (n = 145) | (n = 2) | (n = 6) 6174delT | 5.5 |
*
Familial was defined as two first-degree relatives with pancreatic adenocarcinoma but do not fulfill the criteria for other familial cancer syndromes. No Ashkenazi Jewish heritage.
†
Families with three or more cases of pancreatic cancer with at least two cases in first-degree relatives. Six families of Ashkenazi Jewish descent.